Bipolar Radio Frequency as an Adjunct to Face and Body Contouring: A 745-Patient Clinical Experience

2021 ◽  
Author(s):  
Jonathan Cook ◽  
Barry E DiBernardo ◽  
Jason N Pozner
Keyword(s):  
Adverse Events ◽  
Clinical Experience ◽  
Chart Review ◽  
Body Contouring ◽  
Specific Treatment ◽  
Retrospective Chart Review ◽  
The Body ◽  
New Paradigm ◽  
Skin Laxity ◽  
Fat Removal

Abstract Background Radiofrequency (RF) technology has ushered in a new paradigm in body contouring for patients with mild to moderate skin laxity who desire fat removal without exacerbating skin laxity issues. The authors utilized a bipolar internal RF device as an adjunct to liposuction and found the device to simpler and more accurate than previous technologies. Objectives Our study aims to review our clinical experience with bipolar RF assisted liposuction (RFAL). Methods A review of our large experience with bipolar RFAL was completed, with evaluation of the nuances from appropriate patient selection and specific treatment areas. The authors treated 745 patients from January 2017 to January 2020 at two centers. A retrospective chart review was performed of the first and last 50 patients treated at each center (for a total of 100 patients in each group), to assess trends in outcomes and adverse events. Results Results were generally excellent from physician evaluation, and overall patient satisfaction was high (96%). The two most common adverse events were temporary swelling (9%) and nodules (8.5%). Selected examples of a variety of cases are reviewed. Conclusions The ability to tighten skin with a minimally invasive tool adds much to the contemporary approach to the body contouring patient with skin laxity. Adverse events were minimal and greatly decreased after an initial short learning curve. Bipolar RFAL is a strong addition to our surgical armamentarium and has become one of the essential tools for our practices.

Retrospective Chart Review of Cryopreserved Amniotic Membrane for Knee Pain

2020 ◽  
Author(s):  
Ruben Berrocal Timmons
Keyword(s):  
Quality Of Life ◽  
Adverse Events ◽  
Amniotic Membrane ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Final Analysis ◽  
Mean Values ◽  
Number Of Patients ◽  
The Impact

Objective: Treatment of joint pain with an injection of the amniotic membrane has not been adequately studied. This study retrospectively reviewed Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and analgesic usage data from patients treated with the injection of cryopreserved amniotic membrane (CAM) in their knees to determine the impact of treatment on patients’ pain, quality of life, and analgesic usage. Methods: Chart review was conducted on 40 patients. Institutional Review Board (IRB) approval was obtained prior to initiation of the project. The membrane was utilized as per the FDA guidance of 21CFR1271. Retrospective data, including demographics, medical history, pain score, quality of life score, analgesic usage and adverse events, were collected from their medical records for each consenting patient through 6 months after CAM injection. Results: A total of 40 patients were considered in the final analysis. Mean VAS for pain level improved from 7.0 to 2.6 (p<0.001). WOMAC daily activity function score improved from a mean score of 52 to 28 (p<0.001). Opioid and non-steroidal anti-inflammatory drug (NSAID) usage decreased from 97% to 25% (p<0.001). No adverse events were reported. Conclusion: Mean values for VAS and WOMAC scores significantly improved at all time points and the number of patients who used analgesics decreased as compared to baseline. CAM injection into painful knee joints decreases pain, improves physical function, and decreases the use of analgesics in the absence of adverse events.

scholarly journals Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults

2016 ◽  
Vol 3 (2) ◽  
Author(s):  
Tara A. Lindeman ◽  
Joan M. Duggan ◽  
Eric G. Sahloff
Keyword(s):  
Human Immunodeficiency Virus ◽  
Clinical Trials ◽  
Adverse Events ◽  
Serum Creatinine ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Integrase Inhibitor ◽  
Serious Adverse Events ◽  
Immunodeficiency Virus ◽  
Human Immunodeficiency Virus 1

Abstract This retrospective chart review evaluated changes in serum creatinine and creatinine clearance (CrCl) after initiation of an integrase inhibitor (INSTI)-based regimen as initial treatment in human immunodeficiency virus-infected adults. Serum creatinine and CrCl changes were similar to those seen in clinical trials for INSTIs. No renal-related serious adverse events or discontinuations occurred.

scholarly journals Unusual obstetric trauma in newborn

2020 ◽  
Vol 9 ◽  
pp. 21
Author(s):  
Haif Assia ◽  
Ketfi Mounir ◽  
Achouri Djelloul ◽  
Sinacer Samira ◽  
Soualili Zineddine
Keyword(s):  
Umbilical Cord ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Birth Trauma ◽  
The Body ◽  
Facial Trauma ◽  
Bilateral Pneumothorax ◽  
Pertinent Data ◽  
Cord Injury ◽  
The Impact

Background: Birth injuries during delivery are rare but can be the most common cause of morbidity and mortality. All parts of the body can be damaged. The aim of this study is to determine the impact of these uncommon injuries on the newborn. This is a retrospective chart review of 11 newborn babies who had concurrent birth trauma. Pertinent data on the cause of injury treatment and the outcome were recorded. Methods: It is a retrospective chart review of newborns who sustained a birth trauma during delivery. These patients presented to the Department of Pediatric Surgery, SETIF, Algeria from 2010 to 2020. Results: A total of 11 cases with birth trauma occurred during delivery were managed during the study tenure. Of these 11, 9 were males and 2 females. Two cases sustained scalp laceration including one extensive laceration exposing the brain tissue with uncontrollable hemorrhage. One newborn sustained facial trauma secondary to the forceps delivery. One newborn who needed resuscitation and ventilation at birth developed bilateral pneumothorax secondary to the barotrauma. One patient sustained a femur fracture whereas another had a humerus fracture along with brachial plexus injury during delivery. Three cases had umbilical cord injury including two cases of clamped hernia of the umbilical cord resulting in neonatal intestinal obstruction. Two cases had scrotal trauma including one with testicular evisceration. Two cases were expired in this cohort. Conclusion: We have presented a diversity of birth trauma in newborns and their management. Proper antenatal follow-up and better planning for the delivery can avoid such injuries in newborns which often require surgical interventions for the management and at times can lead to mortality as well.

Retrospective Chart Review of Cutaneous Adverse Events Associated with Tremelimumab in 17 Patients

2018 ◽  
Vol 19 (6) ◽  
pp. 899-905 ◽  
Author(s):  
Macartney Welborn ◽  
Shelby L. Kubicki ◽  
Naveen Garg ◽  
Anisha B. Patel
Keyword(s):  
Adverse Events ◽  
Chart Review ◽  
Retrospective Chart Review

Assessment of Adverse Events Associated With Antiretroviral Regimens for Postexposure Prophylaxis for Occupational and Nonoccupational Exposures to Prevent Transmission of Human Immunodeficiency Virus

2007 ◽  
Vol 28 (6) ◽  
pp. 695-701 ◽  
Author(s):  
A. Luque ◽  
S. Hulse ◽  
D. Wang ◽  
U. Shahzad ◽  
E. Tanzman ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Occupational Exposure ◽  
Adverse Events ◽  
Healthcare Workers ◽  
Health Program ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Preventive Treatment ◽  
Postexposure Prophylaxis ◽  
Immunodeficiency Virus

Objective.To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF).Methods.Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP.Setting.University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center.Participants.Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004.Results.We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure.Conclusion.Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.

scholarly journals Clinical Experience with the M4 Ahmed Glaucoma Drainage Implant

2017 ◽  
Vol 11 (3) ◽  
pp. 92-96 ◽  
Author(s):  
Ilya Sluch ◽  
Brett Gudgel ◽  
Justin Dvorak ◽  
Mary Anne Ahluwalia ◽  
Kai Ding ◽  
...  
Keyword(s):  
Clinical Experience ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Primary Outcome Measure ◽  
Ahmed Valve ◽  
Pressure Spike ◽  
Surgical Failure ◽  
Hypertensive Phase ◽  
Study Inclusion

ABSTRACT Aim To evaluate the safety and efficacy of the M4 (porous polyethylene plate) Ahmed Glaucoma Valve (AGV) drainage implant in a multicenter retrospective study. Materials and methods A retrospective chart review of medical records of patients who had undergone the M4 Ahmed valve was performed from January 2013 to April 2015. The primary outcome measure was surgical failure defined as: Less than a 20% reduction in baseline intraocular pressure (IOP) to last follow-up visit, final IOP less than 5 mm Hg or greater than 18 mm Hg, reoperation for glaucoma, or loss of light perception vision. All eyes not meeting the above criteria were defined as success. Results A total of 291 eyes met all study inclusion criteria. The average follow-up in the study was 6 months (±7.6 months) with 112 patients achieving 12-month follow-up (38.5%). 208 eyes (71.5%) met the study success criteria at final follow-up. No statistically significant spikes in postoperative IOP at 1 and 4 months were detected. The average preoperative IOP was 26.0 on an average of 2.8 medications. At 6 months, the average IOP dropped to 16.7 on 0.9 medications and stayed relatively stable at 15.8 on 1.2 medications at 12-month follow-up. Conclusion The M4 valve appears to have less of a hypertensive phase compared with the other Ahmed class valves with a similar safety profile. While 71.5% success rate was achieved at final follow-up, the failure rate steadily increased over time. Clinical significance While the M4 production has been discontinued, the porous design of the M4 may avoid a pressure spike in the Ahmed valve class and warrants future investigation for valve design. How to cite this article Sluch I, Gudgel B, Dvorak J, Ahluwalia MA, Ding K, Vold S, Sarkisian S. Clinical Experience with the M4 Ahmed Glaucoma Drainage Implant. J Curr Glaucoma Pract 2017;11(3):92-96.

scholarly journals Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia

2021 ◽  
Author(s):  
Jing-Zhou Hou ◽  
Kellie Ryan ◽  
Senxi Du ◽  
Bruno Fang ◽  
Stanley Marks ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Chronic Lymphocytic Leukemia ◽  
Adverse Events ◽  
Dose Reduction ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Routine Clinical Practice ◽  
Lymphocytic Leukemia ◽  
First Line ◽  
Dose Reductions

Aim: A retrospective chart review of ibrutinib-treated patients with chronic lymphocytic leukemia (CLL) was conducted. Patients & methods: Adults with CLL who initiated ibrutinib were followed for ≥6 months (n = 180). Results: Twenty-five percent of first-line ibrutinib patients experienced ≥1 dose reduction, mainly due to adverse events (AEs; 79%). Treatment discontinuations and dose holds occurred in 20 and 34% of patients, respectively, most commonly due to AEs (73 and 74%). Approximately one-quarter of relapsed/refractory ibrutinib patients experienced ≥1 dose reduction, mainly due to AEs (88%). Treatment discontinuation and dose holds occurred in 40% of patients (58 and 76% due to AEs, respectively). Conclusion: Dose reductions, holds and discontinuations were frequent in patients with CLL receiving ibrutinib in routine clinical practice.

Sign in / Sign up

Export Citation Format

Share Document